December 6, 2016
Theravance Biopharma Receives FDA Fast Track Designation for Velusetrag (TD-5108) for Idiopathic and Diabetic Gastroparesis
December 5, 2016
Theravance Biopharma Highlights Filing of EU Regulatory Submission for the Closed Triple in COPD by GlaxoSmithKline and Innoviva
November 22, 2016
Theravance Biopharma to Present at the 28th Annual Piper Jaffray Healthcare Conference
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: